Recent Advances in Clinical Application of Panax Notoginseng Saponins in Cardiovascular Diseases

doi:10.12114/j.issn.1007-9572.2020.00.623

Abstract

Abstract:

Panax notoginseng is a traditional Chinese medicine that has a significant effect on cardiovascular diseases for its effect of promoting blood circulation and removing blood stasis. With the development of techniques for extracting herb drugs， improved purity of Panax notoginseng extract greatly improves its efficacy. In this paper， we reviewed recent literature concerning Panax notoginseng extract 〔 with Panax notoginseng saponins（ PNS） as the main component〕 in the treatment of cardiovascular diseases （ coronary heart disease， hypertension， heart failure， arrhythmia）， and analyzed and summarized the mechanism of action， clinical effect and possible adverse reactions of PNS， and concluded that PNS and its active ingredients
have definite curative effects on cardiovascular diseases. Moreover， PNS may produce a variety of pharmacodynamic effects on
coronary heart disease， hypertension， heart failure， arrhythmia or coexisting cardiovascular diseases， thereby reducing the
economic and mental pressures and improving quality of life of the patients.

Key words: , Cardiovascular diseases；Panax notoginseng；Panax notoginseng saponins；Sanchinoside；Cardiovascular agents（TCD）

摘要： 三七作为我国传统中药，因其具有活血化瘀的功效，在治疗心血管疾病方面疗效显著，且随着现代中药提取技术的提高，三七提取物极大程度地提高了其作用功效。整理近几年国内外关于三七提取物（主要成分为三七总皂苷）在治疗心血管疾病（冠心病、高血压、心力衰竭、心律失常）时的作用机制、临床应用效果及可能的不良反应等文献，并对所查阅的相关文献进行相应的剖析、归纳及总结。本文结论为三七提取物三七总皂苷及其有效成分对治疗心血管疾病有明确疗效，尤其是在冠心病、高血压、心力衰竭、心律失常或多种疾病同时合并存在时，三七提取物三七总皂苷可起到使用单一药物而发挥多种药效的作用，同时减轻患者经济及精神压力，提高患者生活质量。

关键词: 心血管疾病, 三七, 三七总皂苷, 三七皂甙, 心血管药物（中药）

LU Shuli,FENG Yan,GAO Jie, et al. Recent Advances in Clinical Application of Panax Notoginseng Saponins in Cardiovascular Diseases　[J]. Chinese General Practice, 2021, 24(5): 539-545. DOI: 10.12114/j.issn.1007-9572.2020.00.623.
卢淑立,冯妍,高杰等. 三七提取物在心血管疾病临床应用中的研究进展[J]. 中国全科医学, 2021, 24(5): 539-545. DOI: 10.12114/j.issn.1007-9572.2020.00.623.

References

［1］胡盛寿，高润霖，刘力生，等.《中国心血管病报告2018》概要［J］.中国循环杂志，2019，34（3）：209-220.DOI：10.3969/j.issn.1000-3614.2019.03.001.
HU S S，GAO R L，LIU L S，et al.Summary of the 2018 report on cardiovascular diseases in China［J］.Chinese Circulation Journa，2019，34（3）：209-220.DOI：10.3969/j.issn.1000-3614.2019.03.001.
［2］杨娟，袁一怔，尉广飞，等.三七植物化学成分及药理作用研究进展［J］.世界科学技术-中医药现代化，2017，19（10）：1641-1647.DOI：10.11842/wst.2017.10.009.
YANG J，YUAN Y Z，WEI G F，et al.Research progress in chemical constituents and pharmacological action of panax notoginseng［J］.World Science and Technology-Modernization of Traditional Chinese ，2017，19（10）：1641-1647.DOI：10.11842/wst.2017.10.009.
［3］郑丽华，卢昌均，周志昆，等.HPLC测定三七总皂苷中5种皂苷的含量及稳定性考察［J］.中医药临床杂志，2012，24（1）：73-75.
ZHENG L H，LU C J，ZHOU Z K，et al.Determination of five saponins in total saponins of notoginseng by HPLC and its stability［J］.Clinical Journal of Traditional Chinese Medicine，2012，24（1）：73-75.
［4］宁冰冰，陈瑜，张腾.三七及其主要皂苷组分在心血管疾病中的作用研究进展［J］.中国中医药信息杂志，2017，24（10）：126-129.DOI：10.3969/j.issn.1005-5304.2017.10.034.
NING B B，CHEN Y，ZHANG T.Research progress in the effects of Notoginseng radix et rhizoma and its main saponins in cardiovascular diseases［J］.Chinese Journal of Information on Traditional Chinese Medicine，2017，24（10）：126-129.DOI：10.3969/j.issn.1005-5304.2017.10.034.
［5］陈雅慧，傅春升，孙爱萍，等.三七总皂苷制剂研究进展［J］.中南药学，2018，16（6）：812-816.DOI：10.7539/j.issn.1672-2981.2018.06.019.
CHEN Y H，FU C S，SUN A P，et al.Progress of preparations of total saponins in Panax notoginseng［J］.Central South Pharmacy，2018，16（6）：812-816.DOI：10.7539/j.issn.1672-2981.2018.06.019.
［6］LIU Y，HAO F，ZHANG H G，et al.Panax notoginseng saponins promote endothelial progenitor cell mobilization and attenuate atherosclerotic lesions in apolipoprotein E knockout mice［J］.Cell Physiol Biochem，2013，32（4）：814-826.DOI：10.1159/000354484.
［7］FAN C M，CHEN Q N，REN J Y，et al.Notoginsenoside R1 suppresses inflammatory signaling and rescues renal ischemia-reperfusion injury in experimental rats［J］.Med Sci Monit，2020，26：e920442.DOI：10.12659/MSM.920442.
［8］祁宏，董彦文.血栓通粉针治疗不稳定型心绞痛疗效观察［J］.中华临床医师杂志（电子版），2011，5（19）：5801-5803.DOI：10.3877/cma.j.issn.1674-0785.2011.19.055.
QI H，DONG Y W.Observation on therapeutic effect of Xueshuantong powder injection on unstable angina pectoris［J］.Chinese Journal of Clinicians（Electronic Edition），2011，5（19）：5801-5803.DOI：10.3877/cma.j.issn.1674-0785.2011.19.055.
［9］KAUL S.The“no reflow”phenomenon following acute myocardial infarction：mechanisms and treatment options［J］.Journal of Cardiology，2014，64（2）：77-85.DOI：10.1016/j.jjcc.2014.03.008.
［10］丰冠鹏，魏运亮，白雁，等.STEMI患者PCI术中冠状动脉注射三七总皂甙的临床效果［J］.实用医药杂志，2017，34（2）：143-145.DOI：10.14172/j.issn1671-4008.2017.02.016.
FENG G P，WEI Y L，BAI Y，et al.Clinical effect of total saponins of Panax notoginseng in PCI of STEMI patients［J］.Practical Journal of Medicine & Pharmacy，2017，34（2）：143-145.DOI：10.14172/j.issn1671-4008.2017.02.016.
［11］罗建华，王超.血栓通对老年冠心病介入术后患者血清炎症因子和血液流变学指标的影响［J］.中国老年学杂志，2018，38（14）：3358-3360.DOI：10.3969/j.issn.1005-9202.2018.14.011.
LUO J H，WANG C.Effect of Xueshuantong on serum inflammatory factors and hemorheology in elderly patients with coronary heart disease after intervention［J］.Chinese Journal of Gerontology，2018，38（14）：3358-3360.DOI：10.3969/j.issn.1005-9202.2018.14.011.
［12］王阶，许军，衷敬柏，等.三七总苷对高黏血症患者血小板活化分子表达和血小板聚集的影响［J］.中国中西医结合杂志，2004，24（4）：312-316.DOI：10.3321/j.issn：1003-5370.2004.04.007.
WANG J，XU J，ZHONG J B，et al.Effect of radix notoginseng saponins on platelet activating molecule expression and aggregation in patients with blood hyperviscosity syndrome［J］.Chinese Journal of Integrated Traditional and Western Medicine ，2004，24（4）：312-316.DOI：10.3321/j.issn：1003-5370.2004.04.007.
［13］王文婷，薛梅，杨琳，等.三七总皂苷基于花生四烯酸代谢通路保护胃黏膜和增强阿司匹林抗血小板作用的实验研究［J］.中西医结合心脑血管病杂志，2019，17（9）：1315-1320.DOI：10.12102/j.issn.1672-1349.2019.09.009.
WANG W T，XUE M，YANG L，et al.Experimental research on the protective effect of Panax notoginseng saponins on the gastrc mucosa and the anti-platelet effect aspirin based on arachidonic acid metabolic pathway［J］.Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascuiar Disease，2019，17（9）：1315-1320.DOI：10.12102/j.issn.1672-1349.2019.09.009.
［14］刘长清.三七总皂苷对血瘀证AMI患者PCI术后抗栓及炎症反应的临床评价［D］.武汉：湖北中医药大学，2019.
LIU C Q.The clinical evaluation of Panax notoginseng sapanins on antitithrombotic and inflammatory responses after PCI in patients with acute myocardial infarction［D］.Wuhan：Hubei University of traditional Chinese Medicine，2019.
［15］阎小燕，崔德芝，杨清峰.三七皂甙联合阿司匹林对老年冠心病患者血小板聚集功能的影响［J］.山东医药，2015，55（41）：47-48.DOI：10.3969/j.issn.1002-266X.2015.41.018.
YAN X Y，CUI D Z，YANG Q F.Effect of Panax notoginsenoside combined with aspirin on platelet aggregation in elderly patients with coronary heart disease［J］.Shandong Medical Journal，2015，55（41）：47-48.DOI：10.3969/j.issn.1002-266X.2015.41.018.
［16］WANG Q，MU R F，LIU X，et al.Steaming changes the composition of saponins of Panax notoginseng（Burk.）F.H.Chen that function in treatment of hyperlipidemia and obesity［J］.J Agric Food Chem，2020，68（17）：4865-4875.DOI：10.1021/acs.jafc.0c00746.
［17］DONG Y，DUAN L，CHEN H W，et al.Network pharmacology-based prediction and verification of the targets and mechanism for panax notoginseng saponins against coronary heart disease［J］.Evidence-Based Complementary and Alternative Medicine，2019，2019：6503752.DOI：10.1155/2019/6503752.
［18］王妮.血栓通注射液对急性冠脉综合征患者介入术后血脂、炎症因子及内皮功能的影响［J］.现代中西医结合杂志，2017，26（7）：728-730.DOI：10.3969/j.issn.1008-8849.2017.07.015.
WANG N.Effect of Xueshuantong Injection on blood lipid，inflammatory factors and endothelial function in patients with acute coronary syndrome after intervention［J］.Modern Journal of Integrated Traditional Chinese and Western Medicine，2017，26（7）：728-730.DOI：10.3969/j.issn.1008-8849.2017.07.015.
［19］LU J，LU Y，WANG X，et al.Prevalence，awareness，treatment，and control of hypertension in China：data from 1.7 milloin adults in a population-based screening study（China PEACE Million Persons Project）［J］.Lancet，2017，390（10112）：2549-2558.
［20］LOH Y C，TAN C S，CH’NG Y S，et，al.Mechanisms of action of Panax notoginseng ethanolic extract for its vasodilatory effects and partial characterization of vasoactive compounds［J］.Hypertension Research，2019，42（2）：182-194.DOI：10.1038/s41440-018-0139-9.
［21］YANG Y，XI P，XIE Y，et al.Notoginsenoside R1 reduces blood pressure in spontaneously hypertensive rats through a long non-coding RNA AK094457［J］.Int J Clin Exp Pathol，2015，8（3）：2700-2709.
［22］袁伟.复方血栓通胶囊治疗原发性高血压的临床研究［J］.中外医疗，2015，（34）：132-133.DOI：10.16662/j.cnki.1674-0742.2015.34.132.
YUAN W.Clinical study on the treatment of essential hypertension with the com pound of the compound capsule［J］.China Foreign Medical Treatment，2015，（34）：132-133.DOI：10.16662/j.cnki.1674-0742.2015.34.132.
［23］冷雪，张立德，贾连群，等.人参皂苷 Rb1对异丙肾上腺素诱导大鼠急性心肌缺血影响的作用机制［J］.中国实验方剂学杂志，2015，21（24）：104-108.DOI：10.13422/j.cnki.syfjx.2015240104.
LENG X，ZHANG L D，JIA L Q，et al.Effect of Ginsenoside Rb1 on isoproterenol-nduced acute myocardial ischemia in rats and its mechanism of action［J］.Chinese Journal of Experimental Traditional Medical Formulae，2015，21（24）：104-108.DOI：10.13422/j.cnki.syfjx.2015240104.
［24］陈业，范育玲，展磊.复方血栓通胶囊联合阿司匹林治疗高血压性视网膜病变的临床研究［J］.深圳中西医结合杂志，2019，29（20）：36-37.DOI：10.16458/j.cnki.1007-0893.2019.20.016.
CHEN Y，FAN Y L，ZHAN L.Clinical study on the treatment of hypertensive retinopathy with compound Xueshuantong capsule and aspirin［J］.Shenzhen Journal of Integrated Traditional Chinese and Western Medicine，2019，29（20）：36-37.DOI：10.16458/j.cnki.1007-0893.2019.20.016.
［25］李钢铁.血栓通联合洛汀新治疗高血压病肾损害疗效观察［J］.中国中医急症，2006，15（6）：604-605.DOI：10.3969/j.issn.1004-745X.2006.06.024.
LI G T.Observation on the curative effect of Xueshuantong combined with Lotensin in the treatment of renal damage in hypertension［J］.Journal of Emergency in Traditional Chinese Medicine，2006，15（6）：604-605.DOI：10.3969/j.issn.1004-745X.2006.06.024.
［26］王淑香，赵强.p38MAPK 在心力衰竭发病机制中的研究进展［J］.医学综述，2014，20（19）：3486-3488.DOI：10.3969/j.issn.1006-2084.2014.19.012.
WANG S X，ZHAO Q.Research progress of the role of p38MAPK in the pathogenesis of heart failure［J］.Medical Recapitulate，2014，20（19）：3486-3488.DOI：10.3969/j.issn.1006-2084.2014.19.012.
［27］李舒承，王虹，黄贤胜，等.三七总皂苷对慢性心力衰竭大鼠心脏功能、血浆利钠肽及血管紧张素Ⅱ的影响［J］.东南大学学报（医学版），2019，38（4）：638-642.DOI：10.3969/j.issn.1671-6264.2019.04.014.
LI S C，WANG H，HUANG X S，et al.Effects of Panax notoginseng saponins on cardiac function，plasma natriuretic peptide and angiotensinⅡ in rats with chronic heart failure［J］.Journal of Southeast University（Medical Science Edition），2019，38（4）：638-642.DOI：10.3969/j.issn.1671-6264.2019.04.014.
［28］SHAO M Y，GUO D Q，LU W J，et al.Identification of the active compounds and drug targets of Chinese medicine in heart failure based on the PPARs-RXRα pathway［J］.J Ethnopharmacol，2020，257：112859.DOI：10.1016/j.jep.2020.112859.
［29］杨兰.血栓通针剂联合西药常规治疗慢性心力衰竭随机平行对照研究［J］.实用中医内科杂志，2014，28（2）：108-110.DOI：10.13729/j.issn.1671-7813.2014.02.53.
YANG L.Xueshuantong injection combined with western conventional random parallel control study of chronic heart failure［J］.Journal of Practical Traditional Chinense Internal Medicine，2014，28（2）：108-110.DOI：10.13729/j.issn.1671-7813.2014.02.53.
［30］SELVENDRAN S，AGGARWAL N，LI J，et al.The role of myocardial fibrosis in determining the success rate of ablation for the treatment of atrial fibrillation［J］.Minerva Cardioangiol，2017，65（4）：420-426.DOI：10.23736/S0026-4725.17.04371-7.
［31］康玲玲，高端敏.三七皂苷R1对心房颤动大鼠心肌炎症相关因子和金属基质蛋白酶表达的影响［J］.中山大学学报（医学版），2019，40（6）：921-929.DOI：10.13471/j.cnki.j.sun.yat-sen.univ（med.sci）.2019.0127.
KANG L L，GAO D M.Effects of notoginsenoside R1 on expression of myocardial inflammation-related factors and metalloproteinase in atrial fibrillation rats［J］.Journal of Sun Yat-sen University（Medical Sciences），2019，40（6）：921-929.DOI：10.13471/j.cnki.j.sun.yat-sen.univ（med.sci）.2019.0127.
［32］MA S Y，MA J，MAI X Y，et al.Danqi soft capsule prevents infarct border zone remodelling and reduces susceptibility to ventricular arrhythmias in post-myocardial infarction rats［J］.Journal of Cellular and Molecular Medicine，2019，23（8）：5454-5465.DOI：10.1111/jcmm.14428.
［33］匡荣仁，胡中华，莫壁伶，等.三七总皂甙联合胺碘酮对阵发性房颤P波离散度和超敏C-反应蛋白的影响［J］.广西医学，2014，36（8）：1117-1119.DOI：10.11675/j.issn.0253-4304.2018.08.30.
KUANG R R，HU Z H，MO B L，et al.Effect of Panax notoginsenosides combined with amiodarone on P wave dispersion and high sensitivity C-reactive protein in patients with paroxysmal atrial fibrillation［J］.Guangxi Medical Jorunal，2014，36（8）：1117-1119.DOI：10.11675/j.issn.0253-4304.2018.08.30.
［34］匡荣仁，原丽萍，贺献芝，等.三七总皂苷联合胺碘酮对阵发性房颤左心房内径和心锚重复蛋白的影响［J］.天津中医药，2018，35（8）：573-575.DOI：10.11656/j.issn.1672-1519.2018.08.04.
KUANG R R，YUAN L P，HE X Z，et al.Effects of Panax notoginsenosides combined with amiodarone on left atrial diameter and anchor repeat protein in patients with paroxysmal atrial fibrillation［J］.Tianjin Journal of Traditional Chinese Medicine，2018，35（8）：573-575.DOI：10.11656/j.issn.1672-1519.2018.08.04.
［35］HEPNER D L，CASTELLS M C.Anaphylaxis during the perioperative period［J］.Anesth Analg，2003，97（5）：1381-1395.DOI：10.1213/01.ane.0000082993.84883.7d.
［36］李黎明，金若敏，符胜光，等.清开灵、血塞通注射液类过敏反应研究［J］.中国中医药信息杂志，2014，21（9）：53-57.DOI：10.3969/j.issn.1005-5304.2014.09.016.
LI L M，JIN R M，FU S G，et al.Studies on anaphylactoid reactions induced by traditional Chinese medicine injections of Qingkailing and Xuesaitong［J］.Chinese Journal of Information on Traditional Chinese Medicine，2014，21（9）：53-57.DOI：10.3969/j.issn.1005-5304.2014.09.016.
［37］黄爱群.三七总皂苷注射剂致药物不良反应分析［J］.深圳中西医结合杂志，2018，28（6）：72-73.DOI：10.16458/j.cnki.1007-0893.2018.06.035.
HUANG A Q.Analysis of adverse drug reactions caused by Panax Notoginsenoside injection［J］.Shenzhen Journal of Integrated Traditional Chinese and Western Medicine March，2018，28（6）：72-73.DOI：10.16458/j.cnki.1007-0893.2018.06.035.
［38］周自强，胡大一，陈捷，等.中国心房颤动现状的流行病学研究［J］.中华内科杂志，2004，43（7）：491-494.DOI：10.3760/j.issn：0578-1426.2004.07.005.
ZHOU Z Q，HU D Y，CHEN J，et al.An epidemiological survey of atrial fibrillation in China［J］.Chinese Journal of Internal Medicine，2004，43（7）：491-494.DOI：10.3760/j.issn：0578-1426.2004.07.005.

[1]	WANG Fang，DENG Hongyue，CAO Guili，SHEN Qiang. Effectiveness of Family Doctor Services and Associated Factors in Dongcheng District，Beijing　 [J]. Chinese General Practice, 2021, 24(22): 2805-2809.
[2]	CHEN Haijing，XIN Zhong，WANG Xuhong，YU Caiguo. Comparison of the Value of Anthropometric Indicators and Triglycerides Glucose Index in the Diagnosis of Metabolic Syndrome　 [J]. Chinese General Practice, 2020, 23(7): 813-818.
[3]	JIANG Shaoqing，PAN Xuanren，PANG Zongqin，PANG Jiyan. Prognostic Value of Pediatric Critical Illness Score in Combination with Glasgow Coma Scale and Video EEG Monitoring in Severe Viral Encephalitis in Children　 [J]. Chinese General Practice, 2020, 23(27): 3402-3407.
[4]	WANG Zhuoya1，2，YANG Faman，ZHOU Hongmei，LIU Ji，WANG Yuanjun，LI Xiaoping，JING Zehui. Relationship of Abnormal Coagulation with Plasma TF-MPs and P-selectin in Patients with Chronic Mountain Sickness　 [J]. Chinese General Practice, 2020, 23(27): 3416-3421.
[5]	ZHAO Bentian，JIANG Haitao，WANG Ling，LIU Qianshu，WANG Hong. Clinical Study of Esophageal Motility and Reflux in Patients with Typical and Atypical Symptoms of Gastroesophageal Reflux Disease　 [J]. Chinese General Practice, 2020, 23(15): 1904-1909.
[6]	LIN Beilei，MEI Yongxia，ZHANG Zhenxiang，LIU Lamei，ZHANG Yan，WANG Yongli，WANG Wenna，GUO Yunfei. Research Progress on Decisional Balance Tools of Health-related Behaviors　 [J]. Chinese General Practice, 2020, 23(13): 1599-1605.
[7]	WANG Jiayu，ZHANG Ping，LI Xuebin，GUO Jihong. Correlation between Echocardiographic Mechanical Synchrony Parameters and Efficiency of Cardiac Resynchronization Therapy　 [J]. Chinese General Practice, 2019, 22(23): 2805-2810.
[8]	. Plasma 6-Ketoprostaglandin F1α Level of Patients with Coronary Heart Disease Combined with Diabetes and Follow-up Studies [J]. Chinese General Practice, 2016, 19(25): 3040-3045.
[9]	. Plasma 6-Ketoprostaglandin F1α Level of Patients with Coronary Heart Disease Combined with Diabetes and Follow-up Studies [J]. Chinese General Practice, 2016, 19(25): 3040-3045.
[10]	. Expression of Chemokine CCL20 and Its Receptor CCR6 in Lung Adenocarcinoma and Their Relationship with Recurrence or Metastasis [J]. Chinese General Practice, 2016, 19(25): 3061-3065.
[11]	. [J]. Chinese General Practice, 2016, 19(20): 11-111.